Straumann Holding AG (STMN) Fair Value & Analysis
Healthcare · CH · Market cap CHF 16.7B · ISIN CH1175448666
What is Straumann Holding AG really worth?
A solid business, but trading 99% above our fair value of CHF 47.31.
Strengths
Risks
For context
Fair value as of: Sep 2, 2026
From 26 valuation models · updated 2 days ago
Share price −10.5% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (CHF 61.74). The favourable scenario is already priced in.
- Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (CHF 28.62 to CHF 61.74) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 2, 2026.
How to read this chart
60‑month range CHF 74.97 – CHF 199.75 · fair‑value band CHF 28.62 – CHF 61.74 · the CHF 93.94 price screens above the CHF 47.31 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 2, 2026.
Analysis
Straumann Holding AG (STMN) currently trades at CHF 93.94, while our model-based Fair Value estimate is CHF 47.31, implying the stock looks roughly 98.6% overvalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of CHF 47.39 per share, and 0 of the 26 models we run sit above the CHF 93.94 price. Bear case: the Asset-Based group reads lowest at CHF 9.08, and 26 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Straumann Holding AG generated revenue of CHF 2.6B at a net margin of 13.7%. Revenue grew 2.2% year over year. It earns a return on equity of 17.0%. Net debt stands at CHF 175M. Fundamentals as of Sep 2, 2026
Our scenario range runs from CHF 28.62 (bear case) to CHF 61.74 (bull case); at CHF 93.94, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 15% below its 52-week high and 30% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −50%, STMN screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly CHF 0.8357 per share, which is 1.8 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: DCF Models (CHF 47.39) versus Asset-Based (CHF 9.08). Highest evidence: FCF DCF (79).
Notify me when STMN reaches fair value
Put STMN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Sep 2, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 66 · Market factors (momentum, volatility) 48
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Straumann Holding AG provides tooth replacement and orthodontic solutions in Switzerland, the United States, China, Germany, Brazil, Japan, France, and internationally. It operates through Sales Europe, Middle East and Africa; Sales North America; Sales Asia Pacific; Sales Latin America; and Operations segments.
Full company description
Straumann Holding AG provides tooth replacement and orthodontic solutions in Switzerland, the United States, China, Germany, Brazil, Japan, France, and internationally. It operates through Sales Europe, Middle East and Africa; Sales North America; Sales Asia Pacific; Sales Latin America; and Operations segments. The company offers dental implants, instruments, CADCAM prosthetics, orthodontic and clear aligners, biomaterials, and digital equipment and solutions for use in tooth correction, replacement, and restoration, as well as to prevent tooth loss. It also provides implant systems, components, and related instruments, as well as healing components, materials and surfaces, surgical sets and instruments, and guided surgery and navigation products; prosthetics, including angled solutions, connections, components, and molar solutions; intra-oral and lab scanners, milling machines, dynamic navigation systems, and 3D printers; consumables, such as blocks, discs, resins, titanium bases, and abutment blanks, as well as scan bodies, analogs, and sleeves; online education; and dentists and dental labs solutions. In addition, the company offers regenerative solutions for tooth preservation, implant-site management, and implant preservation; scanner hardware, software licenses, sterile-packaged products, customer training, and other products; and logistics and supply chain services. Further, it provides thermoplastics; implant treatment referral; high-tech materials; artificial intelligence solutions for dental applications; and 3D orthodontic treatment animations. The company sells its products under the Straumann, Neodent, Medentika, Anthogyr, ClearCorrect, NUVO, and other brands through a network of distribution subsidiaries and partners, and third-party distributors, as well as through its e-shop. It serves clinicals needs, patient segments, and healthcare systems. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Straumann Holding AG reported revenue of CHF 2.6B in FY2025 versus CHF 2.0B in FY2021, a compound +6.5%/yr. Reported net income was CHF 358M in FY2025, compounding −2.5%/yr from FY2021.
of which total revenue +13.4 % · buybacks/dilution −0.1 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
STMN screens 99% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 194 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Sep 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $367.07 | $150.04 | −59% |
| EssilorLuxottica Société anonyme EL | €160.35 | €94.93 | −41% |
| Medline Inc MDLN | $36.59 | $30.15 | −18% |
| Becton, Dickinson and Company BDX | $187.12 | $100.46 | −46% |
| Alcon Inc ALC | $72.23 | $39.78 | −45% |
| ResMed Inc RMD | A$33.19 | A$26.23 | −21% |
| West Pharmaceutical Services, Inc WST | $337.47 | $141.58 | −58% |
| Sartorius Stedim Biotech S.A DIM | €197.70 | €48.88 | −75% |
| Sartorius Aktiengesellschaft SRT3 | €253.50 | €63.30 | −75% |
| Coloplast A/S COLOB | kr 435.80 | kr 382.22 | −12% |
Compare Straumann Holding AG with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Straumann Holding AG (STMN) overvalued or undervalued?
What is the fair value of STMN?
What is the quality score of STMN?
What is the revenue of Straumann Holding AG (STMN)?
What is the net profit margin of STMN?
Does Straumann Holding AG pay a dividend?
Watch Straumann Holding AG in the live analysis
One click puts Straumann Holding AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.